Amgen Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AMGN34.SA | BIIB | NVS | 0R1F.IL | GLENMARK.NS | 068270.KS | |
|---|---|---|---|---|---|---|
| Market cap | 1.42T | 37.61B | 311.59B | 137.59B | 700.43B | 49.02T |
| P/E (TTM) | 29.2 | 110.2 | 31.5 | 17.3 | 39.0 | — |
| Forward P/E | — | 15.6 | 16.6 | — | 25.6 | — |
| Price/book | 1.2 | 2.0 | 8.4 | 4.2 | 6.7 | — |
| Dividend yield | 1.49% | — | 2.87% | 4.04% | 0.20% | 0.36% |
| 1-year change | +47.28% | +62.35% | +30.35% | +34.05% | +38.35% | +20.07% |
| Today | +3.49% | +2.22% | +3.59% | +2.89% | −0.91% | +7.50% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 20 min.
Latest news
All AMGN34.SA news ›Amgen projects 2026 revenue of $38.9B-$39.7B while raising non-GAAP EPS to $22.90-$23.70
Amgen Q3 2026 earnings: revenue rose 8%, guidance was raised, and IMDELLTRA stood out. Earnings Call Insights: Amgen (AMGN) Q3 2026 - “For the latest quarter, total revenues grew a strong 8% year-over-year to $10.4 billion.” (Chairman &…
Amgen, Up 41% This Year, Is Broadly Outperforming Its Peers. Here's What Its Earnings Say.
Allison Gatlin covers biotechnology, pharmaceuticals and medical technology. She also oversees coverage of top-performing companies for Investor's Business Daily's The New America page. Allison has worked for Investor's Business Daily…
Amgen posts higher-than-expected third quarter results, but shares dip
Nov 3 (Reuters) - Amgen on Tuesday said third-quarter sales rose 8%, led by cholesterol drug Repatha and newer medicines Imdelltra for lung cancer and rare disease therapy Uplizna, as the company moves ahead with development of its…
Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript
Amgen Inc. (AMGN) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Casey Capparelli - Executive Director of Investor RelationsRobert Bradway - Chairman & CEOMurdo Gordon - Executive Vice President of Global Markets and PolicyJames…
Amgen reports revenue and earnings beat, stock shows little change in extended trading
CNBC Amgen reports revenue and earnings beat, stock shows little change in extended trading
Amgen boosts 2026 guidance following Q3 beats
Seeking Alpha - Amgen (AMGN) increased its revenue and profit guidance ranges for 2026 after releasing Q3 results that beat on both lines. - Full-year revenue is now projected at $38.9B-$39.7B (consensus $38.97B), up from $38B-$39.4B…
Amgen third quarter sales rise 8%, led by cholesterol, cancer drugs
Nov 3 (Reuters) - Amgen on Tuesday said third-quarter sales rose 8%, led by demand for cholesterol drug Repatha and newer medicines Imdelltra for lung cancer and rare disease therapy Uplizna, as the company moves ahead with development of…
Forex Signals Nov 2: AMD, Shopify, Amgen, Booking, Arista Earnings Preview Tuesday
AMD and Arista Networks are likely to attract the most attention as investors look for evidence that data-centre and semiconductor demand can sustain current valuations. Recent capital expenditure figures from Microsoft and Alphabet have…
[Amgen Q3 2026 Earnings Call] Amgen Raises Full-Year Guidance as Revenue Hits $10.4B and IMDELLTRA Shows 21.1-Month Survival in Small Cell Lung Cancer
"Our results through the first three quarters of the year reflect the strength of our business across a broad range of products and pipeline molecules," said CEO Bob Bradway. "This is exactly the kind of performance our strategy was…
Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing Investments and Innovation | AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Amgen, Jazz Pharma, BeiGene, Zymeworks, ALX Oncology
Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing openPR.com Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing Investments and Innovation | AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Amgen, Jazz Pharma,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketbeat.com34
- marketscreener.com32
- seekingalpha.com12
- theglobeandmail.com12
- fool.com11
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.